Researchers are looking for people with myasthenia gravis (MG) to participate in a multinational phase 2A clinical trial to evaluate the safety, tolerability and effectiveness of the investigational drug UCB7665.

UCB7665, under development by UCB Pharma, is administered via subcutaneous (under-the-skin) injection and is designed to reduce the severity of muscle weakness and fatigue in individuals with MG, as indicated via the Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis – Activities of Daily Living profile (MG-ADL) scores.

Trial length is approximately 18 weeks, during which participants will visit with study investigators approximately 20 times.

In order to be eligible to participate, individuals must:

• be at least 18 years old
• have a diagnosis of MG
• meet additional criteria

The trial is taking place at more than a dozen study sites across the United States, and support for travel costs may be available.

To learn more about this trial, visit clinicaltrials.gov and enter NCT03052751 into the “Other Terms” search box, or visit the trial website.